Edwards Lifesciences CEO bets on long-term growth as rivalry heats up
As seen on the 24/7 Wall St. homepage on November 4, 2026.
As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for strong, sustainable growth over the long term.
The CEO is steering investors toward the long game just as Boston Scientific pours $1.5 billion into the heart valve fight, and the $57 billion medtech leader has ticked up slightly since he said it. What matters next is whether third quarter structural heart growth backs up that confidence.
Continue ReadingShow less
Bernard J Zovighian's remarks came during the Q3 2026 earnings call, where he pointed squarely at positioning and sustainability rather than any single quarter's results. That framing is a deliberate signal to investors that Edwards Lifesciences is managing for a multi-year arc, not a short-term beat.
The backdrop makes the tone matter more than it otherwise might. Boston Scientific has committed $1.5 billion to the heart valve space, sharpening the competitive pressure on Edwards in what has long been its core structural heart franchise. A CEO leaning on "long-term" language in that environment is either telegraphing confidence in a durable moat or managing expectations for a bumpier near-term road.
Sponsored
Since Zovighian made the statement, shares have ticked up 0.96%, a modest but positive reaction that suggests the market is at least not pushing back on the message. For a company carrying a $57 billion valuation, even measured upward movement after a broadly optimistic earnings comment reflects a degree of investor buy-in.
The real test comes in whether third-quarter structural heart results substantiate the confidence he expressed. If that segment's growth trajectory holds or accelerates, the long-game framing looks prescient. If it softens while a well-funded rival is spending aggressively, the gap between the CEO's words and the numbers will draw more scrutiny.
Sources
Mentioned: EW